Auriga Research India Pvt Ltd., Research Wing at Arbro Pharmaceuticals, partnered with PerkinElmer, Inc. to conduct testing at Kempegowda International Airport Bengaluru (BIAL). The program will include a COVID-19 sample collection booth near the gates and have a testing facility on the premises at BIAL.
Mr. Hari Marar, President and CEO, Bangalore International Airport Limited (BIAL) said “The well-being of passengers is our utmost priority and it is our core responsibility to provide for everything to keep them safe and sound. This testing facility is a step towards breaking the chain of community spread of the virus”
Dr. Saurabh Arora, Managing Director, Auriga Research and Arbro Pharmaceuticals, said, “This testing facility is NABL approved and is open to the outbound and inbound passengers for on-demand tests as per the ICMR guidelines with provisions to generate reports in 6-8 hours. This Laboratory will also have the capability to check for surface-oriented COVID-19 infection. This will further help to ensure a safe environment for all the travellers and airport authorities.”
“Considering our long-term relationship with Auriga Research, we are excited and proud to be associated with their airport testing facility. PerkinElmer is one of the few companies that provides full workflow solutions for large scale COVID-19 testing, and we think airport screening will make an impact in slowing the spread,” said Shripad Joshi, President, India, and South Asia, PerkinElmer.
-AK
Arya has been a part of the Content & Research Team at Hrnxt.com. She is a keen observer of economic developments, emerging businesses, people in business and keeps a tab on latest happenings in the business environment.